G00001

Annex A

215215

Singapore Patent Application No. 200100653-5
Our Reference : CG/TSF/PAT/8104113/SG
Applicant : Pfizer Products Inc.
Date : 17 March 2003

ARGUMENTS IN RESPONSE TO OBJECTIONS REFERRED TO IN THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

With regard to the Examiner's objection raised in the International Preliminary Examination Report (IPER), the applicant would like to set forth the following arguments.

The applicants have deleted claims 18 and 19 and have amended all the method claims into "Swiss" type claims.

The specification indicates, at page 6, lines 1-15, that in fact the compounds of formula I have $5HT_{1A}$ receptor agonizing activity as well as α2 adrenergic receptor antagonizing activity. The claims are intended to encompass administration of a combination wherein the same compound has the activities recited.

The applicants submit that the above factors and the amendments filed to the Singapore application should establish the validity of the Singapore patent.